Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A9 | P48067 | 9/20 | 0.39 |
| ▸ | SLC6A2 | P23975 | 9/20 | 0.39 |
| ▸ | SLC6A4 | P31645 | 7/20 | 0.39 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.36 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.36 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.36 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.36 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.36 |
| ▸ | CNR2 | P34972 | 1/20 | 0.36 |
| ▸ | SLC6A3 | Q01959 | 6/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17684738 | 0.99 | SLC6A9 (0.39) | SLC6A9SLC6A2SLC6A4CYP3A4CYP2D6 | |
| SCHEMBL17684020 | 0.92 | SLC6A9 (0.38) | SLC6A9SLC6A2CYP2C9CYP2C19 | |
| SCHEMBL17684819 | 0.92 | SLC6A9 (0.38) | SLC6A9CYP3A4CYP2D6CYP2C9CYP2C19 | |
| SCHEMBL17684552 | 0.91 | SLC6A9 (0.48) | SLC6A9 | |
| SCHEMBL17684609 | 0.91 | SLC6A2 (0.41) | SLC6A9SLC6A2SLC6A4 | |
| SCHEMBL17684025 | 0.91 | SLC6A9 (0.39) | SLC6A9SLC6A2CYP2C9CYP2C19 | |
| SCHEMBL17684152 | 0.90 | SLC6A9 (0.36) | SLC6A9 | |
| SCHEMBL17684352 | 0.90 | SLC6A9 (0.41) | SLC6A9CYP3A4CYP2D6CYP2C9CYP2C19 | |
| SCHEMBL17684378 | 0.90 | SLC6A9 (0.41) | SLC6A9CYP3A4CYP2D6CYP2C9CYP2C19 | |
| SCHEMBL17735948 | 0.90 | SLC6A9 (0.41) | SLC6A9CYP3A4CYP2D6CYP2C9CYP2C19 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20160130278-A1 | GLYCINE TRANSPORTER INHIBITOR | TAISHO PHARMACEUTICAL CO., LTD (JP) | 2016-05-12 | — | — | US | claimed |
| EP-3009421-A1 | GLYCINE TRANSPORTER INHIBITOR | Taisho Pharmaceutical Co., Ltd. (JP) | 2016-04-20 | — | — | EP | claimed |
| US-20160130278-A1 | GLYCINE TRANSPORTER INHIBITOR | TAISHO PHARMACEUTICAL CO., LTD (JP) | 2016-05-12 | — | — | US | disclosed |
| US-20160130278-A1 | GLYCINE TRANSPORTER INHIBITOR | TAISHO PHARMACEUTICAL CO., LTD (JP) | 2016-05-12 | — | — | US | disclosed |
| US-20160130278-A1 | GLYCINE TRANSPORTER INHIBITOR | TAISHO PHARMACEUTICAL CO., LTD (JP) | 2016-05-12 | — | — | US | disclosed |
| EP-3009421-A1 | GLYCINE TRANSPORTER INHIBITOR | Taisho Pharmaceutical Co., Ltd. (JP) | 2016-04-20 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160130278-A1 | GLYCINE TRANSPORTER INHIBITOR | SLC1A2, SLC6A5, SLC18A2 | SLC6A9 13/4885SLC6A2 10/4885SLC6A4 12/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.